Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments

Feagan Brian; Vermeire Severine; Sandborn William J.; Reinisch Walter; Tarabar Dino; Su Chinyu; Niezychowski Wojciech; Zhang Haiying; Woodworth Deborah; Yu Dahong; Sands Bruce

首页> 外文期刊>The American Journal of Gastroenterology >Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments

【24h】

Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments

机译：托法替尼在两项三期临床试验中用于活动性溃疡性结肠炎患者的诱导治疗：局部和中央内镜评估的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The American Journal of Gastroenterology》 |2016年第1期|共2页
作者
Feagan Brian; Vermeire Severine; Sandborn William J.; Reinisch Walter; Tarabar Dino; Su Chinyu; Niezychowski Wojciech; Zhang Haiying; Woodworth Deborah; Yu Dahong; Sands Bruce;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments [J] . Feagan Brian, Vermeire Severine, Sandborn William J., The American Journal of Gastroenterology . 2016,第Suppla1期

机译：托法替尼在两项三期临床试验中用于活动性溃疡性结肠炎患者的诱导治疗：局部和中央内镜评估的结果
2. Onset of Efficacy of Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Multinational, Phase 3 Clinical Trials [J] . Sandborn William J., Danese Silvio, Panes Julian, The American Journal of Gastroenterology . 2016,第Suppla1期

机译：在两项跨国的3期国家/地区临床试验中，托法替尼在活动性溃疡性结肠炎患者中进行诱导治疗的疗效开始
3. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies [J] . Motoya Satoshi, Watanabe Mamoru, Kim Hyo Jong, Intestinal research. . 2018,第2期

机译：东亚活动性溃疡性结肠炎患者的Tofacitinib诱导和维持治疗：来自三项三期跨国研究的亚组分析
4. Synbiotic Therapy Significantly Reduces Molecular Markers of Inflammation and Clinical Scores in Patients with Active Ulcerative Colitis; A Randomised Controlled Trial [C] . Controlled Release Society annual meeting . 2004

机译：同步治疗显着减少了活性溃疡性结肠炎患者的炎症和临床评分的分子标记;随机对照试验
5. Application of an active comparator-based benefit-risk assessment in evaluating clinical trial design features of a new chemical entity using a Bayesian decision-theoretic framework. [D] . Goel, Varun. 2010

机译：基于贝叶斯决策理论框架的基于活动比较者的利益风险评估在评估新化学实体的临床试验设计特征中的应用。
6. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies [O] . Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, 2018

机译：东亚活动性溃疡性结肠炎患者的Tofacitinib诱导和维持治疗：来自三项三期跨国研究的亚组分析
7. Clinicopathological Features of Acute Myeloid Leukemia in a Patient with Phase III Clinical Trial of Tofacitinib (Xeljanz) Therapy for Ulcerative Colitis: A Case Study with Literature Review [O] . Ming Xie, Hongwei Ma 2016

机译：急性髓性白血病患者III期临床试验的临床病理学特征（XELJANZ）治疗溃疡性结肠炎 - 以文献综述为例

Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments

著录项

相似文献

相关主题

期刊订阅